ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials
These robust responses were seen across all dose levels and with both apalutamide and darolutamide combinations. Most patients remain on therapy, with several approaching one year or more of treatment.
A scientist examining cells in a lab, representing the company's dedication to developing specialty pharmaceuticals.
Safety data were also encouraging: the vast majority of adverse events were mild or moderate (Grade 1 or 2), primarily gastrointestinal, supporting long-term dosing suitability. Only one patient experienced a Grade 3 event, and there were no severe (Grade 4 or 5) treatment-related adverse events. ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) plans to advance two recommended Phase 2 doses for each combination into further study, with a global Phase 3 trial set to begin in the first half of 2026.
To support these efforts, ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced a $125 million private placement financing led by top healthcare investors, extending its cash runway into the second half of 2027 and through the anticipated Phase 3 trial readout.
While we acknowledge the potential of ORIC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ORIC and that has 100x upside potential, check out our report about this
READ NEXT: and
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
AI and Automation Integration Elevates Laboratory Informatics Demand
The North America laboratory informatics market, valued at USD 1.62 billion in 2024, is set to grow at a CAGR of 4.30% to USD 2.48 billion by 2034. Growth is fueled by cloud-based LIMS, AI, and automation. Pharma and biotech sectors leverage informatics for efficiency, boosting the market with strategic partnerships. North American Laboratory Informatics Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "North America Laboratory Informatics Market Report and Forecast 2025-2034" has been added to offering. The North America laboratory informatics market was valued at USD 1.62 billion in 2024, driven by accelerating demand for cloud-based platforms. It is projected to grow at a CAGR of 4.30% from 2025 to 2034, reaching USD 2.48 billion by 2034. Informatics solutions, including LIMS, ELN, SDMS, and CDS, enhance data accuracy, compliance, and workflow automation in industries like pharmaceuticals and biotechnology. Innovations in cloud computing, AI, and automation are transforming laboratory data management by improving decision-making, regulatory compliance, and productivity. Market Growth Drivers and Trends Adoption of unified digital platforms is propelling market growth. The integration of LIMS and ELN functionalities enhances data security and collaboration. For example, eLabNext rebranded its key products into a centralised Digital Lab Platform in October 2024, aligning with market shifts toward streamlined management. The preference for advanced ELN systems is positively impacting market size. TeselaGen Biotechnology launched an enhanced ELN in December 2024, improving productivity and data management in biotech and pharmaceutical research. Global collaborations are strengthening market value. LabWare engaged with biopharma entities in Ireland in June 2024, facilitating knowledge exchange and technological advancements in LIMS adoption. Integration of AI and Automation The demand for AI-driven automation is elevating market demand. Funding initiatives support development in automated chemical laboratories, accelerating innovation and efficiency. By reducing manual errors, AI integrations boost LIMS and ELN system adoption, driving long-term market growth. Emerging Trends Cloud-Based LIMS: With significant IT sector contributions to GDP, cloud solutions are becoming essential for efficiency and compliance. Partnerships such as Revvity Signals Software with Scitara drive innovations in cloud-based platforms for R&D. AI and Automation: Initiatives like Scialog and LabVantage Solutions' integration of mixed reality demonstrate a shift towards AI-driven laboratory processes, enhancing efficiency and research competitiveness. Strategic Partnerships: Collaborations, such as those by LabVantage, are fuelling regulatory compliance and workflow automation, offering growth opportunities in laboratory informatics. Market Segmentation and Key Players: The market is segmented by product, delivery mode, component, end user, and region, with LIMS leading due to its pivotal role in sample management and workflow automation. Cloud solutions are preferred for scalability, while software advancements drive component value. Pharmaceutical companies hold the largest share, driven by stringent regulatory demands and R&D investments. Their adoption of informatics solutions enhances drug development and compliance. Major companies include Serum Institute of India, CSL Limited, Bharat Biotech, and CanSino Biologics, further shaping market dynamics with innovative solutions and global strategies. Region Analysis The United States dominates the market with strong R&D investments and digitalisation, while Canada shows growth due to government initiatives and cloud platform adoption. Both countries advance laboratory informatics with investments in data management and AI solutions. Conclusion The North America laboratory informatics market continues to grow, driven by technological advancements and strategic initiatives. The emphasis on AI, automation, and cloud solutions fosters efficiency and competition in the biotech, pharmaceutical, and research sectors. Key Attributes: Report Attribute Details No. of Pages 300 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $1.62 Billion Forecasted Market Value (USD) by 2034 $2.48 Billion Compound Annual Growth Rate 4.3% Regions Covered North America For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment North American Laboratory Informatics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
$515M Bet on Musk, AI, and Space: Glade Brook Goes All-In While Others Retreat
Glade Brook Capital Partners just pulled in $515 million for its fourth fund and it's placing its bets on the edge of what's next: AI, space, defense, and fintech. The firm, which already holds stakes in SpaceX, Stripe, and Elon Musk's Neuralink, plans to double down on late-stage tech startups navigating some of the most volatile capital markets in recent memory. Founder Paul Hudson didn't sugarcoat the conditions, calling it the most challenging fundraising environment he's seen in his career even as the fund ended up oversubscribed. Despite the headwinds, Glade Brook is leaning into momentum. It's already backing Musk's xAI and Artisan AI, signaling a clear tilt toward artificial intelligence. That comes on top of a portfolio that includes ramping fintech player Ramp and previously backed giants like Uber (NYSE:UBER) and Airbnb (NASDAQ:ABNB). And in a move that tracks closely with broader market appetite, the firm is betting that innovation in complex, capital-intensive sectors like AI and defense could offer asymmetric upside if timed right. Tesla (NASDAQ:TSLA) remains part of the broader Musk-aligned orbit Glade Brook is exposed to, adding even more edge to its late-stage tech focus. Their 2021 fund a $430 million vehicle reportedly ranks in the top 5% of its vintage, according to private Cambridge Associates data. While past performance doesn't guarantee future returns, it does suggest Glade Brook knows how to play late-stage cycles. In a market where many VCs are stuck in wait-and-see mode, Glade Brook appears to be playing offense betting that when the next wave breaks, it'll be the firms already in position that ride it the farthest. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
Will Palantir Surge After Aug. 4? History's Answer Is Strikingly Clear.
Key Points Palantir stock has soared more than 1,000% in just a few years. Revenue also has climbed as customers rush to get in on Palantir's AI platform. 10 stocks we like better than Palantir Technologies › Palantir Technologies (NASDAQ: PLTR) has been one of the early winners of the artificial intelligence (AI) revolution, and this streak could keep going. Demand has skyrocketed for its AI-powered software platform -- one that's helping governments and commercial customers make game-changing moves. As a result, government and commercial revenue each have been climbing in the double digits quarter after quarter. Since these customers are in the early days of AI adoption, investors can expect more growth for Palantir. Analyst forecasts for AI expansion support this, too, with the overall AI market expected to increase from the billions of dollars today to beyond $2 trillion in just a few years. Investors clearly are excited about all of this as they've piled into Palantir's stock, helping it to soar 1,300% over the past three years. Now, with a catalyst just ahead, you might be wondering if additional gains lie right around the corner -- and whether you should buy the stock. I'll turn to history for some answers. Serving government and commercial customers First, though, it's worth taking a look at how this 20-year-old company soared into the spotlight in recent times. Years ago, Palantir generated most of its growth through government contracts. Today, that remains a key part of the company's business, but the AI boom has helped this tech player reach a broader range of customers. Now, as companies and organizations aim to apply AI to their businesses, they're seeking out Palantir. This software company is in the business of helping customers aggregate and make better use of their data -- even data that's otherwise been inaccessible. Just two years ago, Palantir launched its Artificial Intelligence Platform, or AIP, leveraging the power of AI. Here are a couple of examples of how this works. United Airlines used AIP to gather maintenance write-ups over the past decade and develop a predictive maintenance system for its fleet, and the Cleveland Clinic is relying on AIP to optimize patient placement and general efficiency. AIP can be a strong ally for governments, too, with its ability to highlight potential decisions and outcomes on the battlefield, for instance. All of this has helped power Palantir's earnings higher in recent quarters. In the latest period, the company reported a 71% gain in U.S. commercial revenue, a 45% increase in U.S. government revenue, and raised forecasts for full-year revenue, adjusted income from operations, and adjusted free cash flow. Chief executive officer Alex Karp said there has been a "stampede" toward AI that's been driving demand for Palantir's offerings, and I think it could continue to do so. A potential catalyst on Aug. 4 That brings me to what's happening on Aug. 4. On that day, Palantir will announce second-quarter earnings. Considering the company's strength so far when it comes to earnings and stock performance, you may be wondering whether the stock will roar higher after the report. History shows us that Palantir stock has performed as follows in the two-month period after the past six reports: Earnings report Performance over two months Q1 2025 +8.5% Q4 2024 -0.1% Q3 2024 +92% Q2 2024 +66% Q1 2024 +8% Q4 2023 +37% Data source: Ycharts History's answer is strikingly clear: If Palantir follows the historical trend, it may soar in the weeks following its upcoming earnings report. That's fantastic news for Palantir's current shareholders or anyone who buys the stock in the days to come -- but it's important to remember a couple of things. First, though history may offer us clues about what might happen next, stocks don't always follow their historical trends -- they can surprise us. This means it's not a good idea to rush into Palantir today with the hope of scoring a quick gain. Holding for the long term Second, whether Palantir bursts higher or not over the coming months won't impact overall performance by much if you hold onto the stock for a number of years. This means you don't have to rush into the stock at one particular moment to get in before a catalyst arrives. Considering all of this, is Palantir a buy? That depends on your investment style. Palantir's gains have resulted in a sky-high valuation, so it's not the best fit for value investors. As a growth stock, it's vulnerable to swings in sentiment and economic data, so very cautious investors might also remain on the sidelines or limit their purchase to a small number of shares. However, for investors focused on growth, Palantir makes a fantastic buy today -- whether it soars after Aug. 4 or not -- as it still may be in its early days of development in the explosive AI market. Should you buy stock in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $665,092!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,050,477!* Now, it's worth noting Stock Advisor's total average return is 1,055% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. Will Palantir Surge After Aug. 4? History's Answer Is Strikingly Clear. was originally published by The Motley Fool
